http://media.soundmedicine.org/segments/051814_1.mp3
Of the 26 million people with diabetes, millions might benefit from a new alternative to insulin shots. The FDA is reviewing Afrezza, an inhalable insulin. Paris Roach, M.D., discusses why MannKind decided to develop Afrezza after Pfizer pulled its inhalable insulin from the market in 2007 and what this could mean for diabetics.